Advertisement
U.S. markets closed

SCYNEXIS, Inc. (SCYX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.6800+0.0300 (+1.82%)
At close: 04:00PM EST
1.6600 -0.02 (-1.19%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.6500
Open1.6200
Bid1.6700 x 1300
Ask1.7200 x 900
Day's Range1.6200 - 1.7000
52 Week Range1.1500 - 3.8700
Volume162,426
Avg. Volume216,436
Market Cap62.509M
Beta (5Y Monthly)1.68
PE Ratio (TTM)1.13
EPS (TTM)1.4900
Earnings DateMar 29, 2024 - Apr 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
44% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SCYX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SCYNEXIS, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    13 days agoMorningstar
View more